SunTrust Assumes uniQure BV (QURE) at Buy
Get Alerts QURE Hot Sheet
Price: $5.32 -1.66%
Rating Summary:
23 Buy, 3 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 11
Rating Summary:
23 Buy, 3 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE
SunTrust analyst Robyn Karnauskas assumes coverage on uniQure BV (NASDAQ: QURE) with a Buy rating and a price target of $90.00.
The analyst commented, "QURE is a gene therapy platform company supported by strong science, leading manufacturing, and experienced management. We believe QURE could potentially have both first- and best-in-class gene therapy options in both hemophilia B (EtranaDeZ) and Huntington's disease (AMT-130)."
For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.
Shares of uniQure BV closed at $69.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- William Blair Starts Bentley Systems Inc. (BSY) at Outperform, 'believe the company has several growth levers'
- RBC Capital Starts TruBridge Inc (TBRG) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!